Overview
Examining Recent Evidence Supporting DOAC Use in the Reduction of Thrombotic Events in Diverse Cardiovascular Patients
DOAC Online Clinical Review & Video Panel Discussion
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this clinical commentary, a panel of three faculty experts review clinical data on the use of DOACs for vascular protection in patients with cardiovascular disease. The discussion will provide an in-depth analysis of safety and efficacy data on prophylactic DOAC use for reducing and/or preventing thrombotic events in patients with atherosclerotic disease. The discussion will also examine recently published trial data and interpret potential implications of these findings in the context of complex, diverse patient populations.
This activity is intended for cardiologists and other healthcare providers who care for patients with atherosclerotic disease.
Patients who experience a cardiovascular event or have peripheral artery disease require long-term antithrombotic prophylaxis to reduce the risk of recurrent cardiac events. Formulating complex regimens for secondary prevention of subsequent cardiovascular events and improved long-term cardiovascular outcomes poses a significant clinical challenge, and patients continue to experience events and associated mortality. The purpose of this activity is to review past and current clinical trial evidence investigating anticoagulant use in the reduction of thrombotic events in diverse cardiovascular patients.
Upon completion of this activity, participants will be able to:
• Discuss long-term atherothrombotic risks in patients with stable cardiovascular disease, including coronary artery disease and peripheral arterial disease
• Interpret data from recent clinical trials using antithrombotic therapy for vascular protection
• Formulate comprehensive pharmacological regimens for complex, diverse patient populations
• Discuss long-term atherothrombotic risks in patients with stable cardiovascular disease, including coronary artery disease and peripheral arterial disease
• Interpret data from recent clinical trials using antithrombotic therapy for vascular protection
• Formulate comprehensive pharmacological regimens for complex, diverse patient populations
Sponsored by the Academy for Continued Healthcare Learning (ACHL) and the Indiana University School of Medicine (IUSM).
Supported by an educational grant from Janssen Scientific Affairs, LLC.
Christian T. Ruff, MD, MPH (Chair)
Assistant Professor of Medicine
Harvard Medical School
Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA
Assistant Professor of Medicine
Harvard Medical School
Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA
Joshua A. Beckman, MD, Msc.
Professor of Medicine
Director, Vascular Medicine
Cardiovascular Division
Vanderbilt University Medical Center
Nashville, TN
Marc P. Bonaca, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Investigator, TIMI Study Group
Brigham and Women’s Hospital
Boston, MA
Indiana University School of Medicine requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and IUSM require the speakers to disclose that a product is not labeled for the use under discussion.
The following financial relationships have been provided:
Christian Ruff, MD (Chair)
Consultant: Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Portola
Grant/Research Support: Daiichi Sankyo
Joshua A. Beckman, MD, Msc. (Faculty)
Consultant: Astra Zeneca, Aralez, Janssen, Bristol Myers Squibb, and Bayer
Grant/Research Support: Merck
Marc P. Bonaca, MD, MPH
Consultant: Aralez, AstraZeneca, Bayer, and Merck
Grant/Research Support: AstraZeneca, Merck, and MedImmune
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: The faculty may discuss off-label use of new oral anticoagulants
IUSM, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 65% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Katlyn Cooper at kcooper@achlcme.org
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Indiana University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Indiana University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.